Czura Thornton Ltd. has acquired Chiltern International for an undisclosed amount. Czura Thornton, a private investment group led by Antony Czura and Nick Thornton, has acquired more than 90% of Chiltern, a global CRO, with the remainder expected to be acquired over the next few weeks. Chiltern runs national and international Phase I to Phase IV trials across a broad range of therapeutic areas. The company has offices throughout the U.S., Europe and India, with headquarters in Slough, UK,...